Insmed's Brensocatib Pipeline Setback Conceals Potential Dupixent-Like Launch in 2025.

Insmed's stock doubled in 2025, outperforming both the biotech and broader markets. The company's approval of Brensocatib in December 2025 was a key driver of this performance. However, a recent setback in the drug's pipeline has overshadowed the successful launch of Dupixent-like treatment. Insmed's stock has declined as a result of the setback, but investors should focus on the company's long-term potential.